Esmyle-D Tablet is a combination pharmaceutical formulation containing Domperidone 10 mg and Esomeprazole 20 mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related symptoms and promoting mucosal healing. The combination of these agents offers a synergistic approach by addressing both motility and acid secretion abnormalities, improving patient outcomes in acid reflux and functional dyspepsia. Esmyle-D is typically administered orally, once daily before meals, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with hypersensitivity to either component. Potential side effects include headache, dry mouth, abdominal cramps, and rare extrapyramidal symptoms. Esmyle-D should be used under medical supervision with appropriate monitoring for optimal therapeutic efficacy.